1314 related articles for article (PubMed ID: 26091244)
1. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
2. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal.
Diallo A; Victor JC; Feser J; Ortiz JR; Kanesa-Thasan N; Ndiaye M; Diarra B; Cheikh S; Diene D; Ndiaye T; Ndiaye A; Lafond KE; Widdowson MA; Neuzil KM
Vaccine; 2018 Oct; 36(43):6424-6432. PubMed ID: 30224199
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
7. MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico.
Cruz-Valdez A; Valdez-Zapata G; Patel SS; Castelli FV; Garcia MG; Jansen WT; Arora AK; Heijnen E
Hum Vaccin Immunother; 2018 Feb; 14(2):386-395. PubMed ID: 28925801
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
12. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
13. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.
Della Cioppa G; Vesikari T; Sokal E; Lindert K; Nicolay U
Vaccine; 2011 Nov; 29(47):8696-704. PubMed ID: 21906647
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age.
Zedda L; Forleo-Neto E; Vertruyen A; Raes M; Marchant A; Jansen W; Clouting H; Arora A; Beatty ME; Galli G; Del Giudice G; Castellino F
Pediatr Infect Dis J; 2015 Jan; 34(1):73-8. PubMed ID: 25037034
[TBL] [Abstract][Full Text] [Related]
17. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
18. Oil-in-water emulsion adjuvant with influenza vaccine in young children.
Vesikari T; Knuf M; Wutzler P; Karvonen A; Kieninger-Baum D; Schmitt HJ; Baehner F; Borkowski A; Tsai TF; Clemens R
N Engl J Med; 2011 Oct; 365(15):1406-16. PubMed ID: 21995388
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
